The companies will leverage Iambic's AI platform to improve the efficiency and success of identi

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in imm

AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win.

AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesth

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through e

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk

The capital required to replace a professional salary with investment income swings by more than $2

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study

Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 S

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead

ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving str

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wi

It is certainly a good Dividend King to buy in September.

AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

These three stocks meet multiple criteria for long-term dividend investing success.

AbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immun

R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-ba

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its p

Two portfolios generating identical dividend income can leave one investor thousands of dollars rich

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a

A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put th

Your Medicare premium leaves your Social Security check before you ever see it, but the right divide

SVB Wealth LLC trimmed its position in AbbVie Inc. (NYSE: ABBV) by 4.9% during the undefined quarter

NorthRock Partners LLC increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 3.0% during t

Summit Financial Strategies Inc. cut its stake in AbbVie Inc. (NYSE: ABBV) by 34.4% in the undefined

NewEdge Advisors LLC cut its position in shares of AbbVie Inc. (NYSE: ABBV) by 30.5% during the seco

Waverly Advisors LLC increased its stake in AbbVie Inc. (NYSE: ABBV) by 43.6% in the undefined quart

IFP Advisors Inc reduced its stake in shares of AbbVie Inc. (NYSE: ABBV) by 3.7% during the second q

Empirical Finance LLC grew its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 3.5% during the sec

AbbVie shares are edging higher Friday following Thursday's positive Phase 3 trial results for i

President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Mor

AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety i

These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing sol

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basi

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could bene

AbbVie reports positive Phase 3 results for etentamig, showing higher response rates and improved su

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR,

AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact ad

Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basi

AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer po

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises th

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the pr

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outper

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price ta

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the an